Physician profile
James W Stephens
NPI 1326248774
$2,161.88
in general payments reported to CMS, 2019-2025
27 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $405 · 2020: $439 · 2021: $383 · 2022: $197 · 2023: $294 · 2024: $309 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $737.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $513.96 | 2019-2025 | Collagenase Santyl, Grafix Pl, Oasis |
| Kerecis Limited | $476.83 | 2019-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Abbvie INC. | $195.38 | 2021-2025 | Dalvance |
| Novo Nordisk INC | $155.00 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.28 | 2019-2022 | |
| Boston Scientific Corporation | $98.77 | 2024 | Eluvia |
| Astrazeneca Pharmaceuticals LP | $74.54 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $71.66 | 2020 | |
| Convatec INC. | $50.56 | 2020-2023 | |
| Lilly USA, LLC | $40.00 | 2020-2021 | |
| Abbott Laboratories | $38.56 | 2021 | |
| Aroa Biosurgery Incorporated | $35.66 | 2020 | |
| Integra Lifesciences Corporation | $31.78 | 2019 | |
| Bard Peripheral Vascular, INC. | $27.98 | 2025 | Rotarexs 6 F X 135 Cm |
| Janssen Pharmaceuticals, INC | $25.76 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $21.58 | 2025 | Auryon Laser System 100-120 Vac |
| Astellas Pharma US INC | $17.78 | 2019 | |
| Averitas Pharma INC. | $17.77 | 2023 | Qutenza |
| Paratek Pharmaceuticals, INC. | $17.58 | 2021 | |
| Reprise Biomedical, INC. | $17.31 | 2025 | Miro3d |
| Amgen INC. | $15.40 | 2021 | |
| Reddress USA, INC. | $15.25 | 2023 | |
| Pfizer INC. | $14.79 | 2020 | |
| Amarin Pharma, INC. | $11.99 | 2019 | |
| Dexcom, INC. | $11.70 | 2021 | |
| Medline Industries LP | $11.03 | 2019 | |
| Allergan, INC. | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.